NEW YORK, Sept 10 (Reuters) - Shares of Dynavax Technologies (DVAX.O) rose 71 percent to $3 in premarket trading on Thursday, after regulators gave it the green light to move forward with its experimental hepatitis B vaccine.
For details, see [ID:nN09475398]
(Reporting by Ryan Vlastelica)
© Thomson Reuters 2009 All rights reserved.
UK
US
Made in China: a new 'electromobile'
Lloyds share offer
Business Update: Dubai boosts yen
Hong Kong pink diamond to set record
Business Update: Dubai fears ease
China firm brings back the MG
Dubai debt problems shock
Bargain hunting on Black Friday
UK based bank review poses change
Dubai fears ease in Europe
uk.reuters.com
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
